arrow
M

María Laura Fox

vall d'hebron institute of oncology
H指数:29
被引数:3,255

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia

CALR突变型原发性血小板增多症的分子特征与治疗反应及预后

2026-03-230
OAAI
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)

初步安全性和有效性:Navitoclax联合Ruxolitinib在Janus Kinase抑制剂初治的骨髓纤维化患者中的研究(多中心、开放标签、II期研究REFINE)

2026-03-170
OAAI
Haploidentical Donor vs. Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplant, a GETH-TC Study

单倍型相合供者与错配无关供者在减低强度预处理干细胞移植中的比较,一项GETH-TC研究

2026-01-120
PRE
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study

共存骨髓增殖性肿瘤和淋巴性肿瘤:一项欧洲多中心回顾性研究

2025-10-170
OAAI
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study

虚弱动态及其对接受自体造血干细胞移植治疗多发性骨髓瘤患者生活质量的影响:来自多中心GETH-TC研究的结果

2025-08-120
PRE
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

momelotinib在伴有贫血的骨髓纤维化患者中的真实世界结局:MOMGEMFIN研究的结果

2025-04-171
OA
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
2025-01-070
OAAI
Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

momelotinib 作为替代其他 JAK 抑制剂在贫血性骨髓纤维化患者中的真实世界疗效

BLOOD
IF23.1
2024-11-051
PRE
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

根据Ipset分层,对原发性血小板增多症患者一线羟基脲治疗反应的预后价值

BLOOD
IF23.1
2024-11-050
PRE
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
LEUKEMIA
IF13.4
2024-09-270
PRE
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
LEUKEMIA
IF13.4
2024-08-300
PRE
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT
2024-07-260
OAAI
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies
2024-05-014
PRE
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
2024-03-201
OAAI
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
2024-01-303
OAAI
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study

DNMT3A/TET2/ASXL1突变是真性红细胞增多症患者中与年龄无关的血栓形成危险因素: 一项观察性研究

2024-01-305
OAAI
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
2023-11-013
OAAI